Otsuka

Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Endpoints
Thu, 03/30/23 - 10:02 am
Otsuka
Lundbeck
Alzheimer's disease
FDA
Rexulti
Alzheimer's disease agitation
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Alphabet's Verily to trial antidepressants
Beckers Hospital Review
Thu, 02/2/23 - 10:42 am
Alphabet
Verily
Otsuka
antidepressants
centanafadine
clinical trials
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
FDA greenlights Otsuka subsidiary's bile duct cancer drug
Endpoints
Mon, 10/3/22 - 10:04 am
Otsuka
Taiho Oncology
Lytgobi
bile duct cancer
FDA
TCT 2022 – Otsuka’s renal denervation system shines
EP Vantage
Thu, 09/22/22 - 10:08 am
Otsuka
Recor
devices
Medtech
TCT
renal denervation
Paradise
FDA accepts Otsuka, Lundbeck filing for long-acting schizophrenia drug, teeing up April decision date
Fierce Pharma
Tue, 09/13/22 - 10:50 am
Otsuka
Lundbeck
schizophrenia
FDA
bipolar disorder
Abilify Maintena
Akebia Regains Rights to Anemia Drug After Otsuka Partnership Dissolves
BioSpace
Mon, 07/4/22 - 11:56 pm
Otsuka
Akebia
vadadustat
anemia
Otsuka backs GrayMatters’ digital wearable tech for mental disorders
Pharmaforum
Fri, 01/14/22 - 11:00 am
Otsuka
GrayMatters Health
digital health
mental health
funding
Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs
Fierce Biotech
Thu, 09/30/21 - 10:52 am
Sunovion
Otsuka
biobucks
neuropsychiatric
Otsuka 'Big Kidney' campaign targets HCPs in bid to shift diagnostic standards
Fierce Pharma
Mon, 03/1/21 - 11:06 am
kidney disease
Otsuka
physicians
autosomal dominant polycystic kidney disease
pharma marketing
Otsuka and Click Therapeutics Tap Verily to Go Remote with Trial
Medical Devices and Diagnostics Industry
Sun, 02/28/21 - 11:58 pm
Otsuka
Click Therapeutics
major depressive disorder
clinical trials
Verily
remote clinical trials
Otsuka, Click trial digital depression therapy with Google
Pharmaforum
Thu, 02/25/21 - 09:44 am
Otsuka
Click Therapeutics
Verily
Alphabet
After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
Endpoints
Thu, 12/17/20 - 06:18 pm
Aurinia Pharmaceuticals
lupus nephritis
GSK
Otsuka
Benlysta
Otsuka takes to YouTube, film and more to tackle the emerging mental health pandemic
Fierce Pharma
Mon, 10/19/20 - 10:37 am
Otsuka
mental health
pandemic
YouTube
Palladio bags $20 million Series B to topple a problematic kidney disease drug
Endpoints
Fri, 09/25/20 - 10:33 am
Palladio Biosciences
autosomal dominant polycystic kidney disease
kidney disease
lixivaptan
Otsuka
Samsca
Court approves Otsuka’s bid to buy Proteus for $15M
MedCity News
Fri, 08/21/20 - 12:34 pm
M&A
Otsuka
Proteus Digital Health
bankruptcy
patient adherence
Armed with FDA nod, Otsuka unit Astex preps to launch oral chemotherapy Inqovi
Fierce Pharma
Mon, 08/3/20 - 10:24 am
Otsuka
Astex
FDA
decitabine
blood cancer
FDA Approves At-Home Oral Therapy for MDS
Xtalks
Sat, 07/11/20 - 11:51 am
FDA
Inqovi
MDS
CMML
Otsuka
Astex

Pages